scholarly journals Beta-blockers in COPD: time for reappraisal

2016 ◽  
Vol 48 (3) ◽  
pp. 880-888 ◽  
Author(s):  
Brian Lipworth ◽  
Jadwiga Wedzicha ◽  
Graham Devereux ◽  
Jørgen Vestbo ◽  
Mark T. Dransfield

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in chronic obstructive pulmonary disease (COPD). The use of beta-blockers in COPD has been proposed because of their known cardioprotective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post-myocardial infarction and in heart failure they remain underused due to concerns regarding potential bronchoconstriction, even with cardioselective drugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in older patients with COPD who have other comorbidities. Medium-term prospective placebo-controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long-acting bronchodilator therapy. Several retrospective observational studies have shown impressive reductions in mortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long-term prospective placebo-controlled randomised controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD, including those with silent cardiovascular disease where the situation is less clear.

2021 ◽  
Author(s):  
Yoko Azuma ◽  
Atsushi Sano ◽  
Takashi Sakai ◽  
Satoshi Koezuka ◽  
Hajime Otsuka ◽  
...  

Abstract Background: Chronic obstructive pulmonary disease (COPD) is an important risk factor for postoperative complications and mortality. The utility of several perioperative bronchodilators in patients with COPD requiring surgery for lung cancer has been reported, but the most suitable agent and its specific effect on postoperative long-term prognosis remain unclear. To determine the effects of perioperative combination therapy, using a long-acting muscarinic antagonist (LAMA) and a long-acting β2 agonist (LABA), on preoperative lung function, postoperative morbidity and mortality, and long-term outcome in COPD patients.Methods: Between January 2005 and October 2019, 130 consecutive patients with newly diagnosed COPD underwent surgery for lung cancer. We conducted a retrospective review of their medical records. Patients were divided into 3 groups according to perioperative management: LAMA/LABA (n=64), LAMA (n=23) and rehabilitation only (no bronchodilator) (n=43). Results: Patients who received preoperative LAMA/LABA therapy showed significant improvement in lung function before surgery (p<0.001 for both forced expiratory volume in 1 second (FEV1) and percentage of predicted forced expiratory volume in 1 second (FEV1 %pred). Compared with patients who received preoperative LAMA therapy, patients with LAMA/LABA therapy had significantly improved lung function (ΔFEV1, 223.1 mL vs 130.0 mL, ΔFEV1 %pred, 10.8% vs 6.8%; both p<0.05). There was a trend toward a lower incidence of postoperative complications in the LAMA/LABA group compared with the LAMA and rehabilitation-only groups. In patients with moderate to severe air flow limitation (n=61), those who received LAMA/LABA therapy had significantly longer overall survival and disease-free survival compared with patients in the other groups. Perioperative LAMA/LABA therapy was also associated with lower recurrence rates. Conclusions: Patients who receive perioperative LAMA/LABA for moderate to severe COPD have improved prognosis and better pulmonary function with surgery for lung cancer. We believe this treatment combination is optimal for patients with lung cancer and COPD.


2021 ◽  
pp. 2004594
Author(s):  
Shuo Liu ◽  
Youn-Hee Lim ◽  
Marie Pedersen ◽  
Jeanette T. Jørgensen ◽  
Heresh Amini ◽  
...  

BackgroundWhile air pollution has been linked to the development of chronic obstructive pulmonary disease (COPD), evidence on the role of environmental noise is just emerging. We examined the associations of long-term exposure to air pollution and road traffic noise with COPD incidence.MethodsWe defined COPD incidence for 24 538 female nurses from the Danish Nurse Cohort (age>44 years) as the first hospital contact between baseline (1993 or 1999) and 2015. We estimated residential annual mean concentrations of particulate matter with diameter<2.5 µm (PM2.5) since 1990 and nitrogen dioxide (NO2) since 1970 by the Danish DEHM/UBM/AirGIS modeling system, and road traffic noise (Lden) since 1970 by the Nord2000 model. Time-varying Cox regression models were applied to assess the associations of air pollution and road traffic noise with COPD incidence.Results977 nurses developed COPD during 18.6 years’ mean follow-up. We observed associations with COPD for all three exposures with hazard ratios (HRs) and 95% confidence intervals (CIs) of 1.19 (1.01, 1.41) per 6.26 µg·m−3 for PM2.5, 1.13 (1.05, 1.20) per 8.19 µg·m−3 for NO2, and 1.15 (1.06, 1.25) per 10 dB for Lden. Associations with NO2 and Lden attenuated slightly after mutual adjustment, but were robust to adjustment for PM2.5. Associations with PM2.5 were attenuated to null after adjustment for either NO2 or Lden. No potential interaction effect was observed between air pollutants and noise.ConclusionsLong-term exposure to air pollution, especially traffic-related NO2, and road traffic noise were independently associated with COPD.


2018 ◽  
Vol 4 (2) ◽  
pp. 00012-2018 ◽  
Author(s):  
Marieke L. Duiverman

Long-term noninvasive ventilation (NIV) to treat chronic hypercapnic respiratory failure is still controversial in severe chronic obstructive pulmonary disease (COPD) patients. However, with the introduction of high-intensity NIV, important benefits from this therapy have also been shown in COPD. In this review, the focus will be on the arguments for long-term NIV at home in patients with COPD. The rise of (high-intensity) NIV in COPD and the randomised controlled trials showing positive effects with this mode of ventilation will be discussed. Finally, the challenges that might be encountered (both in clinical practice and in research) in further optimising this therapy, monitoring and following patients, and selecting the patients who might benefit most will be reviewed.


2021 ◽  
Vol 10 (11) ◽  
pp. 849-851
Author(s):  
Renukadevi Mahadevan ◽  
Chaya Sindaghatta ◽  
Vijay Samuel Raj Victor

The patient is a 64-year-old male. He presented with difficulty in breathing and was diagnosed with COPD (chronic obstructive pulmonary disease) ten years back. He is a farmer and an active smoker, of 18 packs / year for 35 years. He began to experience dyspnoea when performing moderate exertion, dyspnoea grading of 3 as denoted by modified medical research council mMRC (Modified Medical Research Council) and productive cough with sputum, usually in the morning. He is on long-term oxygen therapy of 4 litres of oxygen for 16 hours per day for 2 years. He has a history of hospitalisation six times and 5 - 6 emergency consultations for acute exacerbation in the last 3 years. The patient was on regular treatment with long-acting inhaled beta-2 agonist (LABA) inhaler and long-acting anticholinergics or long-acting muscarinic receptor antagonists (LAMA) and corticosteroid (ICS) inhalers 200-400 micrograms (μg) three times a day and mometasone 400 μg, continuously. The patient’s body mass index (BMI) was 20.3 Kg / m2. His blood pressure was 140 / 80 mmHg, heart rate (HR) 74 bpm, respiratory rate (RR) 22 rpm and peripheral oxygen saturation (SpO2) at rest was 95 %. Pulmonary auscultation revealed a diffusely reduced breath sounds, and no alterations were found in cardiac auscultation. The patient’s post-bronchodilator pulmonary function test was 52.2 % of forced expiratory volume in 1 second (FEV1). In the six-minute walk test(6mwt), the patient walked a total distance of 294.4 meters, with variations in heart rate from 74bpm to 128bpm. Whenever peripheral oxygen saturation was reduced to 88 %, the patient had taken rest. The patient took rest two times, at the end of the second minute thirtyfive seconds and the end of the fourth minute forty-five seconds. The body-mass index, airflow obstruction, dyspnoea and exercise (BODE) mortality index were used to measure 4 years survival interpretation.1 Saint George’s Respiratory Questionnaire chronic obstructive pulmonary disease (COPD) version (SGRQ-C) was used to measure the quality of life (QoL). After the initial assessment, the patient was enrolled in the pulmonary rehabilitation program. The first three months were supervised, exercise training constituted weekly educational sessions and meeting with the psychology support group and nutrition advice before beginning the exercise intervention. 2 The patient visited the institution three days per week for exercise training. The exercise constituted aerobic on the treadmill and intensity, in the beginning, was 80 % of the 6MWT speed, and Borg’s scale of perceived exertion was 4 as prescribed by American Thoracic Society (ATS). 3 The components of the program were warm-up sessions, conditioning, resistance exercise and a cool-down session. The patient was also advised home exercise program, which included resistance training using weighted sandbags for three sessions per week. The resistance added was based on 1 repetition maximum (RM) and 10RM. 80 % of 10 RM was the training intensity for resistance training for a larger group of muscles. 4 The weight was added gradually and ensured their rated perceived exertion (RPE) was at 4 during exercise. The patient’s outcomes were recorded after three months of training. After 12 weeks of supervised outpatient exercise intervention, the patient was advised home exercise program for the next 6 months. 5


2021 ◽  
Vol 2 (1) ◽  
pp. 70-75
Author(s):  
N. A. Karoli ◽  
A. V. Borodkin ◽  
A. P. Rebrov

Objective: to reveal the features of the use of beta-blockers (BB) in patients with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) in real clinical practice.Materials and methods: the study included 90 patients with COPD and CHF, and 41 patients with CHF of ischemic genesis without COPD.Results: patients with COPD and CHF were significantly less likely to receive beta-blockers (BB) compared with patients with CHF. Of the BB patients with COPD and CHF were primarily prescribed bisoprolol, its average dose was 4.45 ± 1.74 mg per day. Patients with COPD and CHF of ischemic genesis of BB were prescribed significantly more often, and diuretics were significantly less likely than patients with COPD and CHF without myocardial infarction. Patients with COPD and CHF with ejection fraction of the left ventricle (LVEF) more than 40% were less likely to take BB than patients with COPD and CHF with reduced EF (less than 40%), and also less frequently, than patients with CHF without COPD with LVEF more than 40%.Conclusion: BB, as first-line drugs in the treatment of CHF, was prescribed on an outpatient basis only to half of patients with COPD and CHF, which does not comply with current guidelines for the management of patients with comorbid conditions. In the vast majority of cases, highly selective BB were prescribed. It should be noted low doses of BB, the absence of dose titration, which does not correspond to modern recommendations for the treatment of chronic heart failure.


BMJ ◽  
2018 ◽  
pp. k4388 ◽  
Author(s):  
Yayuan Zheng ◽  
Jianhong Zhu ◽  
Yuyu Liu ◽  
Weiguang Lai ◽  
Chunyu Lin ◽  
...  

AbstractObjectiveTo compare the rate of moderate to severe exacerbations between triple therapy and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease (COPD).DesignSystematic review and meta-analysis of randomised controlled trials.Data sourcesPubMed, Embase, Cochrane databases, and clinical trial registries searched from inception to April 2018.Eligibility criteriaRandomised controlled trials comparing triple therapy with dual therapy or monotherapy in patients with COPD were eligible. Efficacy and safety outcomes of interest were also available.Data extraction and synthesisData were collected independently. Meta-analyses were conducted to calculate rate ratios, hazard ratios, risk ratios, and mean differences with 95% confidence intervals. Quality of evidence was summarised in accordance with GRADE methodology (grading of recommendations assessment, development, and evaluation).Results21 trials (19 publications) were included. Triple therapy consisted of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA), and inhaled corticosteroid (ICS). Triple therapy was associated with a significantly reduced rate of moderate or severe exacerbations compared with LAMA monotherapy (rate ratio 0.71, 95% confidence interval 0.60 to 0.85), LAMA and LABA (0.78, 0.70 to 0.88), and ICS and LABA (0.77, 0.66 to 0.91). Trough forced expiratory volume in 1 second (FEV1) and quality of life were favourable with triple therapy. The overall safety profile of triple therapy is reassuring, but pneumonia was significantly higher with triple therapy than with dual therapy of LAMA and LABA (relative risk 1.53, 95% confidence interval 1.25 to 1.87).ConclusionsUse of triple therapy resulted in a lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD.Study registrationProspero CRD42018077033.


Sign in / Sign up

Export Citation Format

Share Document